Pharmaq success acknowledged

According to Animal Pharm, the decision was partially based on the fact that Zoetis purchased Pharmaq, in November, “for a fee that was ten times the value of the aquaculture vaccine firm's annual sales” – a deal that “sent out shockwaves, as Zoetis secured the services of one of the leading innovators in the fastest growing segment of animal health industry."

Moreover, from 2005 to 2014, Pharmaq's top line posted a compound annual growth rate of 17%.

"It is with great pleasure and pride that we received the news about this award," said Morten Nordstad, President of Pharmaq. "The fact that our products and innovations have been noticed and ranked to this level gives us motivation to carry on our efforts to support the global aquaculture industry with health products. We are humbled to have won this prize in competition with other skilled and well reputed companies that we highly respect."

Established in 1985, Pharmaq has around 200 employees and is headquartered in Oslo, with subsidiaries in Chile, the UK, Vietnam, Spain, Turkey, Panama and Hong Kong.

The ?rm sells a range of AlphaJect injectable vaccines for treatment of furunculosis, vibriosis, coldwater vibriosis, winter sore, infectious pancreatic necrosis, infectious salmon anemia, salmonid rickettsia septicaemia, enteric septicaemia disease and atypical furunculosis. It also sells parasiticides such as AlphaMax, to protect farmed salmon from sea lice.

Pharmaq's dip vaccines protect against vibriosis and pasteurellosis. The company's prescription therapeutics include anesthetics and antimicrobial powders. The company also runs Pharmaq Analytiq as a sister company. This business provides analysis services to the salmon industry, while in September 2015, Pharmaq's diagnostic division became functional.